Anti-CD33 chimeric antigen receptor T cell therapy(ZIOPHARM Oncology, Inc.)(Anti-CD33 chimeric antigen receptor T cell therapy(ZIOPHARM Oncology, Inc.))

概要

基本信息

药物类型

CAR-T

别名-

靶点

CD33

作用机制

CD33调节剂(髓系细胞表面抗原CD33调节剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤血液及淋巴系统疾病

在研适应症

急性髓性白血病

非在研适应症-

原研机构

Alaunos Therapeutics, Inc.

在研机构

Alaunos Therapeutics, Inc.

Precigen, Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 Anti-CD33 chimeric antigen receptor T cell therapy(ZIOPHARM Oncology, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD33 chimeric antigen receptor T cell therapy(ZIOPHARM Oncology, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD33 chimeric antigen receptor T cell therapy(ZIOPHARM Oncology, Inc.) 相关的专利（医药）

登录后查看更多信息

1

项与 Anti-CD33 chimeric antigen receptor T cell therapy(ZIOPHARM Oncology, Inc.) 相关的文献（医药）

2015-01-01·Molecular Therapy1区 · 医学

Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

1区 · 医学

Article

作者: Han, Qing-wang ; Lv, Hai-yan ; Guo, Bo ; Wang, Li-li ; Fan, Hui ; Wang, Yao ; Wang, Quan-shun ; Han, Wei-dong

We conducted a clinical trial to assess the feasibility and efficacy of CD33-directed chimeric antigen receptor-modified T cells (CART-33) for the treatment of refractory acute myeloid leukemia (AML). A 41-year-old male patient with AML was enrolled and received a total of 1.12 × 10(9) autologous CART-33 cells, of which ~38% were transduced with CAR. The CART-33 infusion alone induced rigorous chills and fevers; drastic fluctuations of his preexisting pancytopenia; elevated serum cytokine levels, including interleukin (IL)-6, IL-8, tumor necrosis factor-α, and interferon-γ; slight transient hyperbilirubinemia within 2 weeks; a subsequent intermittent moderate fever; and reversed fluctuation of the pancytopenia. A marked decrease of blasts in the bone marrow was observed on examination 2 weeks after therapy, and there was a gradual increase until florid disease progression occurred at 9 weeks after the cell infusion. These observations warrant further research on CART-33 treatment in refractory AML and may spur efforts to extend the CART-33-induced tumor burden to the preparation of other intensive strategies, such as hematopoietic stem cell transplantation. This study is registered at www.ClinicalTrials.gov as NCT01864902.

100 项与 Anti-CD33 chimeric antigen receptor T cell therapy(ZIOPHARM Oncology, Inc.) 相关的药物交易

登录后查看更多信息